摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[2-Chloro-4-(dimethylamino)phenyl]-8-[2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-5,7-dimethoxychromen-4-one

中文名称
——
中文别名
——
英文名称
2-[2-Chloro-4-(dimethylamino)phenyl]-8-[2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-5,7-dimethoxychromen-4-one
英文别名
——
2-[2-Chloro-4-(dimethylamino)phenyl]-8-[2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-5,7-dimethoxychromen-4-one化学式
CAS
——
化学式
C25H29ClN2O5
mdl
——
分子量
473.0
InChiKey
XLFDMLSQFBLVRT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    33
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    71.5
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES
    申请人:Nicholas Piramal India Limited
    公开号:EP1556375A2
    公开(公告)日:2005-07-27
  • [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE<br/>[FR] INHIBITEURS DE KINASES DEPENDANTES DES CYCLINES ET LEUR UTILISATION
    申请人:NICHOLAS PIRAMAL INDIA LTD
    公开号:WO2004004632A2
    公开(公告)日:2004-01-15
    The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), wherein R1, R2, R3, R4, R5, R6, R7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of such compounds, methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, use of such compounds in the treatment and prophylaxis of diseases, and to the use of the compounds in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing such compounds either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing such compounds of either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.
查看更多